Adicet Bio (ACET) Liabilities and Shareholders Equity (2017 - 2026)

Adicet Bio's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $169.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 11.44% year-over-year to $169.4 million; the TTM figure through Mar 2026 stood at $665.2 million (down 28.19% YoY), while the FY2025 annual figure was $192.4 million, down 12.65% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $169.4 million, down from $192.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $354.3 million in Q3 2022, with the low at $140.5 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $246.0 million (2024), against an average of $250.8 million.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 37.76% in 2022, then tumbled 42.89% in 2025.
• Adicet Bio's Liabilities and Shareholders Equity stood at $330.7 million in 2022, then plunged by 37.31% to $207.3 million in 2023, then rose by 6.23% to $220.2 million in 2024, then retreated by 12.65% to $192.4 million in 2025, then fell by 11.94% to $169.4 million in 2026.
• Business Quant data shows ACET's Liabilities and Shareholders Equity at $169.4 million in Q1 2026, $192.4 million in Q4 2025, and $140.5 million in Q3 2025.